Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term special drug use-results surveillance for Mayzent in SPMS patients
jRCT2031200377Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of siponimod in secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started Sep 2020; status: completed.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on jRCT2031200377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200377.